Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
==================================================================================================================================================================================================================

* Rikke B. Holmgaard
* David A. Schaer
* Yanxia Li
* Stephen P. Castaneda
* Mary Y. Murphy
* Xiaohong Xu
* Ivan Inigo
* Julie Dobkin
* Jason R. Manro
* Philip W. Iversen
* David Surguladze
* Gerald E. Hall
* Ruslan D. Novosiadly
* Karim A. Benhadji
* Gregory D. Plowman
* Michael Kalos
* Kyla E. Driscoll